A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination
Marco Ranzani, Kristel Kemper, Magali Michaut, Oscar Krijgsman, Nanne Aben, Vivek Iyer, Kim Wong, Theodoros I. Roumeliotis, Martin Del Castillo Velasco-Herrera, Jérémie Nsengimana, Gemma Turner, Nicola Thompson, Aida Shahrabi, Marcela Sjoberg, Mamunur Rashid, Anneliese O. Speak, Vera Grinkevich, Fiona Behan, David Tamborero, Francesco Iorio, Stijn van Dongen, Graham R. Bignell, Clara Alsinet, Sofia Chen, Emmanuelle Supper, Ken Dutton-Regester, Antonia Pritchard, Chi Wong, Anton Enright, Julia Newton-Bishop, Ultan McDermott, Nicholas K. Hayward, Jyoti S. Choudhary, Kosuke Yusa, Lodewyk Wessels, Mathew J. Garnett, Daniel Peeper, David J. Adams
bioRxiv 195354; doi: https://doi.org/10.1101/195354
